CoherenMI Logo
  • Home
  • Latest Insights
  • Industries
  • About Us
  • Contact Us

      Contact Us

      United States

      +1-252-477-1362

      United Kingdom

      +44-203-957-8553/
      +44-203-949-5508

      Australia

      +61-8-7924-7805

      India

      +91-848-285-0837

      For Business Enquiry :

      sales@coherentmi.com

      Sales Office (U.S.) :

      Coherent Market Insights Pvt Ltd, 533 Airport Boulevard, Suite 400, Burlingame, CA 94010, United States.

      Sales Office (U.K.) :

      Coherent Market Insights Pvt Ltd, Office 15811, 182-184 High Street North, East Ham, London E6 2JA, United Kingdom.

      Asia Pacific Intelligence Center (India) :

      Coherent Market Insights Pvt Ltd, Office No 401-402, Bremen Business Center, University Road, Aundh, Pune – 411007, India.

      Menu

      About UsIndustriesServicesContact Us

      Readers Club

      Latest InsightsBlogsPress Release

      Help

      Become ResellerHow to Order?Privacy PolicyTerms and ConditionsDisclaimer
      Connect With Us :
      Secure Payment By :
      Payment Method
      9001:2015iso-9001
      27001:2022iso-27001
      Credibility and Certifications :
      Credibility and Certifications860519526
      Credibility and CertificationsCredibility and CertificationsCredibility and Certifications

      For Business Enquiry :

      sales@coherentmi.com

      United States

      +1-252-477-1362

      United Kingdom

      +44-203-957-8553/
      +44-203-949-5508

      Australia

      +61-8-7924-7805

      India

      +91-848-285-0837

      Menu

      About UsIndustriesServicesContact Us

      Readers Club

      Latest InsightsBlogsPress Release

      Help

      Become ResellerHow to Order?Privacy PolicyTerms and ConditionsDisclaimer

      Sales Office (U.S.) :

      Coherent Market Insights Pvt Ltd, 533 Airport Boulevard, Suite 400, Burlingame, CA 94010, United States.

      Sales Office (U.K.) :

      Coherent Market Insights Pvt Ltd, Office 15811, 182-184 High Street North, East Ham, London E6 2JA, United Kingdom.

      Asia Pacific Intelligence Center (India) :

      Coherent Market Insights Pvt Ltd, Office No 401-402, Bremen Business Center, University Road, Aundh, Pune – 411007, India.

      Credibility and Certifications :

      Credibility and Certifications860519526
      Credibility and CertificationsCredibility and CertificationsCredibility and Certifications

      Secure Payment By :

      Payment Method
      9001:2015iso-9001
      27001:2022iso-27001
      Connect With Us :
      © 2026 CoherentMI. All Rights Reserved.
      Powered by Coherent Market Insights Pvt. Ltd.
      Global Peripheral Arterial Disease Market to be USD 8.25 Bn, 2032

      Published Date: Oct 2025


      The global peripheral arterial disease market, valued at USD 5.14 Billion in 2025, is projected to exhibit a CAGR of 7.0%, reaching USD 8.25 Billion by 2032.

      Market growth is primarily driven by the increasing prevalence of peripheral arterial disease among aging populations, rising incidence of cardiovascular risk factors such as diabetes, hypertension, and obesity, and growing awareness of early diagnosis and intervention. Advancements in minimally invasive endovascular procedures, innovative pharmacological therapies, and combination treatment approaches are further fueling the market expansion.

      Additionally, supportive healthcare infrastructure, improved reimbursement policies, and enhanced investment in clinical research aimed at improving patient outcomes are expected to sustain the market growth over the forecast period.

      Market Takeaways

      • By Treatment, Drug Therapy (including antiplatelets and anticoagulants) is expected to dominate the peripheral arterial disease market with a 55.3% share in 2025, driven by their proven efficacy in improving blood flow, reducing the risk of clot formation, and inclusion in standard treatment protocols for managing peripheral arterial disease.
      • By Disease, Peripheral Arterial Disease itself is projected to lead the market with a 60.2% share in 2025, attributed to its higher prevalence compared with other vascular conditions, growing awareness of early diagnosis, and increased focus on timely intervention to prevent complications such as critical limb ischemia.
      • By Patient Type, the Adult segment is anticipated to account for the largest share in 2025, supported by the high incidence of peripheral arterial disease among adults with cardiovascular risk factors, lifestyle-related comorbidities, and the rising adoption of preventive and therapeutic interventions.
      • Regionally, North America is expected to hold the largest market share in 2025, backed by advanced healthcare infrastructure, high prevalence of cardiovascular diseases, strong reimbursement policies, and ongoing clinical research focused on novel peripheral arterial disease therapies and minimally invasive procedures.

      Global Peripheral Arterial Disease Market Report Coverage

      The full report is now available for purchase: https://www.coherentmi.com/industry-reports/peripheral-arterial-disease-market

      Report Coverage 

      Details 

      Market Revenue in 2025 

      USD 5.14 Billion

      Estimated Value by 2032 

      USD 8.25 Billion

      Growth Rate 

      Poised to exhibit a CAGR of 7.0% 

      Historical Data 

      2020-2024 

      Forecast Period 

      2025–2032 

      Forecast Units 

      Value (USD Billion) 

      Report Coverage 

      Revenue Forecast, Competitive Landscape, Growth Factors, and Trends 

      Segments Covered 

      • By Treatment, Disease and Patient

      Geographies Covered 

      North America (U.S. and Canada), Latin America (Brazil, Argentina, Mexico, and Rest of Latin America), Europe (Italy, Spain, U.K., Germany, France, Russia, and Rest of Europe), Asia Pacific (China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific), Middle East (GCC Countries, Israel, and Rest of Middle East), and Africa (South Africa, North Africa, and Central Africa) 

      Growth Drivers 

      • Rising Prevalence of Cardiovascular Diseases and Improved Diagnostic Capabilities
      • Advancements in Minimally Invasive Therapies

      Trends  

      • Growing Emphasis on Preventive Care and Lifestyle Modifications
      • Integration of Artificial Intelligence (AI) in Diagnosis and Treatment Planning

      Opportunities 

      • Growing Investment in Research for Drug-eluting Devices for Market
      • Increasing Focus on Expanding Treatment Options for Underserved Regions

      Restraints & Challenges 

      • High Cost of Advanced Therapies, Limiting Accessibility
      • Regulatory Challenges and Slower Drug Approval Processes

      Market Dynamics

      The global peripheral arterial disease market is experiencing steady growth, driven by the rising prevalence of peripheral arterial disease and other vascular disorders among adult and elderly populations, increasing awareness about cardiovascular health, and advancements in pharmacological and interventional therapies. Early diagnosis through routine cardiovascular screenings, primary care check-ups, and public health awareness campaigns is facilitating timely treatment, which is critical for improving patient outcomes and preventing severe complications such as critical limb ischemia and amputation.

      Innovations in treatment approaches are reshaping the market, with developments in novel antiplatelet and anticoagulant therapies, minimally invasive endovascular interventions, and combination treatment strategies enhancing efficacy and patient adherence. Drug therapies such as antiplatelets and anticoagulants remain widely used, while emerging therapies targeting vascular remodeling, inflammation, and thrombosis prevention are gaining traction. Endovascular interventions, including balloon angioplasty and stenting, are increasingly integrated with pharmacological treatments for holistic management.

      Hospitals, specialized cardiovascular care centers, and outpatient clinics continue to be the primary end users, supported by trained healthcare professionals, advanced infrastructure, and access to multidisciplinary treatment programs. Telemedicine platforms and remote monitoring devices are emerging as growth avenues, enabling broader patient reach, real-time follow-up, and adherence to therapy outside traditional clinical settings.

      Despite the positive outlook, market growth faces challenges such as patient non-compliance, delayed diagnosis due to asymptomatic cases in early stages, high procedural and therapy costs, and limited access to specialized care in developing regions. However, ongoing product innovation, expanded public health initiatives, and increased clinical research investments are expected to sustain market momentum through 2032.

      Market Trends

      • Growing Emphasis on Preventive Care and Lifestyle Modifications

      There is a growing focus on preventive care and lifestyle modifications in managing peripheral arterial disease. Healthcare providers are promoting non-invasive approaches such as supervised exercise programs, tailored diets, and structured smoking cessation as first-line therapies to improve symptoms, walking ability, and quality of life. These strategies help manage the disease effectively while reducing cardiovascular risks and limb-related complications. This shift toward patient-centered, non-pharmacological care is influencing treatment paradigms, expanding peripheral arterial disease management beyond traditional drug or surgical interventions, and emphasizing long-term lifestyle improvements for better clinical outcomes.

      • Integration of Artificial Intelligence (AI) in Diagnosis and Treatment Planning

      Artificial Intelligence (AI) is increasingly being utilized to enhance the diagnosis and treatment planning for peripheral arterial disease. AI algorithms are being developed to analyze medical imaging data, predict disease progression, and assist in personalized treatment strategies. This integration aims to improve diagnostic accuracy and optimize patient outcomes.

      In October 2022, researchers at Stanford University developed an automated tool to identify undiagnosed peripheral arterial disease cases. This tool, tested using a digital dashboard, aims to bring potential peripheral arterial disease cases to doctors’ attention, enhancing early detection and treatment planning.

      Market Opportunities

      • Integration of Telemedicine and Remote Patient Monitoring

      The increasing adoption of telemedicine and remote monitoring solutions is creating new opportunities in the management of peripheral arterial disease. Wearable devices, mobile health apps, and connected monitoring platforms allow continuous tracking of patient symptoms, blood flow, and exercise compliance. This facilitates early intervention, timely adjustments to therapy, and improved adherence to lifestyle modifications and pharmacological treatments. By enabling healthcare providers to remotely manage patients, reduce hospital visits, and personalize care plans, these digital health solutions are expected to enhance patient outcomes and expand the reach of peripheral arterial disease care, driving the market growth over the forecast period.

      • Expansion of Minimally Invasive Treatment Options

      The growing adoption of minimally invasive procedures, such as angioplasty, stenting, and atherectomy, is transforming the management of peripheral arterial disease. These approaches offer patients significantly reduced recovery times, lower risk of complications, and improved overall outcomes compared to traditional surgical interventions. As clinicians increasingly prefer less invasive techniques, demand for these advanced peripheral arterial disease treatments is rising, creating substantial growth opportunities for medical device manufacturers and healthcare providers focusing on endovascular solutions.

      Analyst View

      • The global peripheral arterial disease market is expected to witness robust growth over the forecast period, driven by its rising prevalence and related cardiovascular conditions among adult and elderly populations. Analysts note that the increasing awareness of early diagnosis, lifestyle modification, and timely intervention is fueling demand for both pharmacological and interventional therapies.
      • From a therapeutic perspective, the market is undergoing a significant evolution. Traditional drug therapies, such as antiplatelets and anticoagulants, continue to hold a substantial share due to established efficacy. However, the rise of minimally invasive endovascular interventions, combination treatment strategies, and emerging gene- and stem-cell-based therapies is reshaping the treatment landscape, offering more personalized and outcome-driven management options for PAD patients.
      • Digital health solutions, including telemedicine platforms, remote patient monitoring, and wearable devices, are increasingly being integrated into patient care. Analysts view these technologies as pivotal in enhancing adherence, facilitating continuous monitoring, and enabling early interventions, particularly for patients in remote or underserved regions.
      • Market opportunities are further amplified by advancements in AI-driven diagnostic tools and predictive algorithms, which improve early detection, risk stratification, and personalized treatment planning. Analysts anticipate that the convergence of pharmacological innovation, minimally invasive procedures, and digital health platforms will create a more comprehensive care ecosystem for PAD management.
      • Key challenges remain, including high costs associated with advanced therapies, regulatory hurdles, delayed diagnosis due to asymptomatic early stages, and limited access in developing regions. Nevertheless, analysts are optimistic that sustained R&D investment, favorable healthcare policies, and technological integration will drive consistent growth in the market. Overall, the market is positioned as a dynamic and evolving segment, combining clinical innovation with digital health trends to address unmet needs in peripheral arterial disease management.

      Key Developments

      • In August 2021, The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) had approved an expanded peripheral artery disease (PAD) indication for the XARELTO (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) to include patients following recent lower-extremity revascularization (LER) due to symptomatic PAD. 

      Competitive Landscape

      • Novartis
      • Bayer
      • Pfizer
      • Amgen
      • Sanofi
      • Novo Nordisk
      • Helixmith
      • AdvanceCor
      • ViroMed

      Peripheral Arterial Disease Market Segmentation

      • By Treatment
        • Drug Therapy (e.g., Antiplatelets, Anticoagulants)
        • Endovascular Therapy
      • By Disease
        • Peripheral Arterial Disease (PAD)
        • Pulmonary Vascular Disease (PVD)
      • By Patient
        • Adult
        • Elderly

      Regional Insights

      • North America
        • U.S.
        • Canada
      • Latin America
        • Mexico
        • Brazil
        • Argentina
        • Rest of Latin America
      • Europe
        • Italy
        • Germany
        • U.K.
        • Spain
        • France
        • Russia
        • Rest of Europe
      • Asia Pacific
        • South Korea
        • India
        • Japan
        • China
        • Australia
        • ASEAN
        • Rest of Asia Pacific
      • Middle East
        • GCC Countries
        • Israel
        • Rest of the Middle East
      • Africa
        • South Africa
        • North Africa
        • Central Africa

      Related Reports :

      • Global Mobile Pet Care Market
      • Global Robotic Prosthetics Market
      • Global Compartment Syndrome Monitoring Devices Market
      • Global Sacroiliac Joint Fusion Market
      1. Press Releases Global Peripheral Arterial Disease Market Expected to Reach USD 8.25 Billion by 2032

      Global Peripheral Arterial Disease Market Expected to Reach USD 8.25 Billion by 2032

      Global Peripheral Arterial Disease Market Expected to Reach USD 8.25 Billion by 2032